Payment overview · 2025
General Payments
$106.59
4 reported records · 4 companies
Healthcare provider profile · identity verified
Nabila Aslam, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BULLHEAD CITY, AZ · NPI 1922089127
Verified facts
What the public records show
CMS Open Payments records show Nabila Aslam, M.D. received $106.59 in general payments during 2025 across 4 reported records.
SI-BONE, INC. accounted for 49.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $52.43 | 49.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $25.42 | 23.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.49 | 13.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.25 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.59 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 920 | 348 |
| Atorvastatin Calcium | Atorvastatin Calcium | 845 | 299 |
| Levothyroxine Sodium | Levothyroxine Sodium | 785 | 240 |
| Losartan Potassium | Losartan Potassium | 694 | 266 |
| Metoprolol Succinate | Metoprolol Succinate | 534 | 186 |
| Lisinopril | Lisinopril | 513 | 186 |
| Metoprolol Tartrate | Metoprolol Tartrate | 426 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 398 | 144 |
| Furosemide | Furosemide | 390 | 140 |
| Pantoprazole Sodium | Pantoprazole Sodium | 388 | 130 |
| Omeprazole | Omeprazole | 385 | 138 |
| Gabapentin | Gabapentin | 344 | 145 |
| Metformin Hcl | Metformin Hcl | 329 | 118 |
| Simvastatin | Simvastatin | 256 | 95 |
| Spironolactone | Spironolactone | 235 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 86 |
| Famotidine | Famotidine | 231 | 103 |
| Montelukast Sodium | Montelukast Sodium | 227 | 84 |
| Tramadol Hcl | Tramadol Hcl | 216 | 60 |
| Azithromycin | Azithromycin | 203 | 164 |
| Prednisone | Prednisone | 199 | 150 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 65 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 188 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 75 |
| Citalopram Hbr | Citalopram Hydrobromide | 186 | 62 |
| Atenolol | Atenolol | 185 | 70 |
| Eliquis | Apixaban | 165 | 55 |
| Allopurinol | Allopurinol | 161 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 79 |
| Potassium Chloride | Potassium Chloride | 152 | 53 |
| Carvedilol | Carvedilol | 146 | 58 |
| Hydralazine Hcl | Hydralazine Hcl | 146 | 73 |
| Januvia | Sitagliptin Phosphate | 140 | 42 |
| Sertraline Hcl | Sertraline Hcl | 139 | 51 |
| Ozempic | Semaglutide | 134 | 37 |
| Finasteride | Finasteride | 127 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 51 |
| Ezetimibe | Ezetimibe | 116 | 44 |
| Valsartan | Valsartan | 114 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 67 |
| Glipizide | Glipizide | 85 | 32 |
| Lovastatin | Lovastatin | 84 | 26 |
| Fluconazole | Fluconazole | 79 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 29 |
| Warfarin Sodium | Warfarin Sodium | 73 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 24 |
| Trazodone Hcl | Trazodone Hcl | 70 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 26 |
| Alendronate Sodium | Alendronate Sodium | 65 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 30 |
| Terazosin Hcl | Terazosin Hcl | 57 | 18 |
| Celecoxib | Celecoxib | 56 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 18 |
| Jardiance | Empagliflozin | 50 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 18 |
| Gemfibrozil | Gemfibrozil | 46 | 14 |
| Mirtazapine | Mirtazapine | 46 | 19 |
| Amoxicillin | Amoxicillin | 44 | 41 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 17 |
| Meloxicam | Meloxicam | 40 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Alprazolam | Alprazolam | 36 | 17 |
| Xarelto | Rivaroxaban | 35 | 14 |
| Novolog Flexpen | Insulin Aspart | 32 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Calcitriol | Calcitriol | 31 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | 14 |
| Nystatin | Nystatin | 30 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | 14 |
| Meclizine Hcl | Meclizine Hcl | 29 | 16 |
| Metformin Hcl Er | Metformin Hcl | 29 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 11 |
| Topiramate | Topiramate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Cephalexin | Cephalexin | 28 | 26 |
| Folic Acid | Folic Acid | 28 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | 11 |
| Acyclovir | Acyclovir | 27 | 12 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | 12 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Clotrimazole | Clotrimazole | 25 | 17 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Naproxen | Naproxen | 25 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 19 |
| Valacyclovir | Valacyclovir Hcl | 24 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 13 |
| Linzess | Linaclotide | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | 11 |
| Novolog | Insulin Aspart | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 14 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Droplet Insulin Syringe | Syrge-Ndl,ins 0.5 Ml Half Mark | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.59 · 4 records | SI-BONE, INC. | FREESTYLE LIBRE 3, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error